Patent: 8,048,872
✉ Email this page to a colleague
Summary for Patent: 8,048,872
Title: | Treatment of hyperproliferative diseases with vinca alkaloid N-oxide and analogs |
Abstract: | The present invention relates to vinca alkaloid and analog N-oxides having activity for treating hyperproliferative disorders. Further, the invention relates to pharmaceutical compositions and methods of using vinca alkaloid and analog N-oxides, alone or in combination with one or more other active agents or treatments, to treat hyperproliferative disorders. |
Inventor(s): | Curd; John G. (Hillsborough, CA), Keana; John F. W. (Eugene, OR), Lalani; Alshad S. (Tarrytown, NY), Westberg; Paul B. (San Mateo, CA), Goodwin; Bradford (San Mateo, CA), Henner; W. David (Tucson, AZ) |
Assignee: | Stat of Oregon Acting by and Through The Oregon State Board of Higher Education on Behalf of the University of Oregon (Eugene, OR) N/A (N/A) |
Application Number: | 12/111,672 |
Patent Claims: | see list of patent claims |
Details for Patent 8,048,872
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Recordati Rare Diseases, Inc. | ELSPAR | asparaginase | For Injection | 101063 | 01/10/1978 | ⤷ Try a Trial | 2026-02-17 |
Merck Teknika Llc | TICE BCG | bcg live | For Injection | 102821 | 06/21/1989 | ⤷ Try a Trial | 2026-02-17 |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | 06/04/1986 | ⤷ Try a Trial | 2026-02-17 |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | ⤷ Try a Trial | 2026-02-17 | |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | Injection | 103132 | ⤷ Try a Trial | 2026-02-17 | |
Amgen, Inc. | EPOGEN/PROCRIT | epoetin alfa | Injection | 103234 | 06/01/1989 | ⤷ Try a Trial | 2026-02-17 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |